Quantcast

Latest CancerVax Stories

2010-03-17 09:50:00

BETHESDA, Md., March 17 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share. The Company received net proceeds from the offering of approximately $75.3...

2010-03-04 06:30:00

BETHESDA, Md., March 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones. "With our lead product candidate blinatumomab expected to begin a European pivotal...

2010-02-25 15:02:00

BETHESDA, Md., Feb. 25 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that the Company will participate in the 2010 RBC Capital Markets Healthcare Conference, to be held March 2 - 3, 2010 in New York City. Christian Itin, Ph.D., the Company's President and CEO, will participate in a panel discussion titled New Targets in Cancer Therapy on March 2, 2010 at 8:00 AM ET. The panel discussion will be webcast live and may be accessed at:...

2010-02-10 10:00:00

BETHESDA, Md., Feb. 10 /PRNewswire-FirstCall/ -- At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S. "We are very pleased with the strong support...

2010-02-04 07:01:00

BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will host a Research & Development Day for the investment community on Wednesday, February 10, 2010 from 8:00 AM - 11:00 AM ET at the Yale Club in New York City. Members of the Company's leadership team will outline near-term development plans for the Company's lead product candidate blinatumomab (MT103) and will provide an update on the Company's earlier stage BiTE®...

2009-12-08 09:00:00

NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL). The data were presented in an oral presentation(1) at the 51st Annual Meeting of the American Society of Hematology (ASH) and were...

2009-12-07 06:00:00

NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a poster(1) with new data from its ongoing phase 1 clinical trial of its product candidate blinatumomab in patients with non-Hodgkin's lymphoma (NHL) at the 51ST Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana....

2009-12-02 06:00:00

BETHESDA, Md., Dec. 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a webcast and conference call on, Tuesday, December 8, 2009, at 12:00 pm Eastern Time (6:00 pm Central European Time) to discuss the blinatumomab data that was presented at the American Society of Hematology (ASH) meeting. To access the webcast...

2009-12-01 05:00:00

BETHESDA, Md., Dec. 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors. Under the terms of the agreement, Bayer Schering Pharma...

2009-11-30 06:00:00

BETHESDA, Md., Nov. 30 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana. Results from the completed phase 2 clinical trial with blinatumomab...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.